Moderna stock slipped Thursday after a Food and Drug Administration advisory committee voted to endorse the company’s experimental coronavirus vaccine for emergency authorization.
Panelists voted 20-0, saying the benefits of Moderna‘s (MRNA) drug outweigh its risks in people ages 18 and older. Dr. Michael Kurilla, an infectious diseases and pathology expert, was the sole panelist to abstain from the vote.
Kurilla took issue with the recommended authorization for people ages 18 and older, saying he’s “not convinced for all of those age groups that the benefits do outweigh the risks.” He said he would rather have seen the drug targeted to people at risk of serious Covid-19.
In after-hours trading on the stock market today, Moderna stock dipped 1.5%. It was unclear immediately why shares dropped. Moderna stock had jumped 5.1% to 144 during the regular session. Shares have posted a sevenfold gain thus far this year. Read More..